Cargando…

Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment

Fulvestrant (F), lapatinib (L), and paclitaxel (P) are hydrophobic, anticancer drugs used in the treatment of estrogen receptor (ER) and epidermal growth factor receptor (EGFR)-positive breast cancer. In this study, glycidylated PAMAM G4 dendrimers, substituted with F, L, and/or P and targeting tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Uram, Łukasz, Wróbel, Konrad, Walczak, Małgorzata, Szymaszek, Żaneta, Twardowska, Magdalena, Wołowiec, Stanisław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489794/
https://www.ncbi.nlm.nih.gov/pubmed/37687164
http://dx.doi.org/10.3390/molecules28176334
_version_ 1785103697019142144
author Uram, Łukasz
Wróbel, Konrad
Walczak, Małgorzata
Szymaszek, Żaneta
Twardowska, Magdalena
Wołowiec, Stanisław
author_facet Uram, Łukasz
Wróbel, Konrad
Walczak, Małgorzata
Szymaszek, Żaneta
Twardowska, Magdalena
Wołowiec, Stanisław
author_sort Uram, Łukasz
collection PubMed
description Fulvestrant (F), lapatinib (L), and paclitaxel (P) are hydrophobic, anticancer drugs used in the treatment of estrogen receptor (ER) and epidermal growth factor receptor (EGFR)-positive breast cancer. In this study, glycidylated PAMAM G4 dendrimers, substituted with F, L, and/or P and targeting tumor cells, were synthesized and characterized, and their antitumor activity against glioma U-118 MG and non-small cell lung cancer A549 cells was tested comparatively with human non-tumorogenic keratinocytes (HaCaT). All cell lines were ER+ and EGFR+. In addition, the described drugs were tested in the context of antinematode therapy on C. elegans. The results show that the water-soluble conjugates of G4P, G4F, G4L, and G4PFL actively entered the tested cells via endocytosis due to the positive zeta potential (between 13.57–40.29 mV) and the nanoparticle diameter of 99–138 nm. The conjugates of G4P and G4PFL at nanomolar concentrations were the most active, and the least active conjugate was G4F. The tested conjugates inhibited the proliferation of HaCaT and A549 cells; in glioma cells, cytotoxicity was associated mainly with cell damage (mitochondria and membrane transport). The toxicity of the conjugates was proportional to the number of drug residues attached, with the exception of G4L; its action was two- and eight-fold stronger against glioma and keratinocytes, respectively, than the equivalent of lapatinib alone. Unfortunately, non-cancer HaCaT cells were the most sensitive to the tested constructs, which forced a change in the approach to the use of ER and EGFR receptors as a goal in cancer therapy. In vivo studies on C. elegans have shown that all compounds, most notably G4PFL, may be potentially useful in anthelmintic therapy.
format Online
Article
Text
id pubmed-10489794
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104897942023-09-09 Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment Uram, Łukasz Wróbel, Konrad Walczak, Małgorzata Szymaszek, Żaneta Twardowska, Magdalena Wołowiec, Stanisław Molecules Article Fulvestrant (F), lapatinib (L), and paclitaxel (P) are hydrophobic, anticancer drugs used in the treatment of estrogen receptor (ER) and epidermal growth factor receptor (EGFR)-positive breast cancer. In this study, glycidylated PAMAM G4 dendrimers, substituted with F, L, and/or P and targeting tumor cells, were synthesized and characterized, and their antitumor activity against glioma U-118 MG and non-small cell lung cancer A549 cells was tested comparatively with human non-tumorogenic keratinocytes (HaCaT). All cell lines were ER+ and EGFR+. In addition, the described drugs were tested in the context of antinematode therapy on C. elegans. The results show that the water-soluble conjugates of G4P, G4F, G4L, and G4PFL actively entered the tested cells via endocytosis due to the positive zeta potential (between 13.57–40.29 mV) and the nanoparticle diameter of 99–138 nm. The conjugates of G4P and G4PFL at nanomolar concentrations were the most active, and the least active conjugate was G4F. The tested conjugates inhibited the proliferation of HaCaT and A549 cells; in glioma cells, cytotoxicity was associated mainly with cell damage (mitochondria and membrane transport). The toxicity of the conjugates was proportional to the number of drug residues attached, with the exception of G4L; its action was two- and eight-fold stronger against glioma and keratinocytes, respectively, than the equivalent of lapatinib alone. Unfortunately, non-cancer HaCaT cells were the most sensitive to the tested constructs, which forced a change in the approach to the use of ER and EGFR receptors as a goal in cancer therapy. In vivo studies on C. elegans have shown that all compounds, most notably G4PFL, may be potentially useful in anthelmintic therapy. MDPI 2023-08-30 /pmc/articles/PMC10489794/ /pubmed/37687164 http://dx.doi.org/10.3390/molecules28176334 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Uram, Łukasz
Wróbel, Konrad
Walczak, Małgorzata
Szymaszek, Żaneta
Twardowska, Magdalena
Wołowiec, Stanisław
Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment
title Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment
title_full Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment
title_fullStr Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment
title_full_unstemmed Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment
title_short Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment
title_sort exploring the potential of lapatinib, fulvestrant, and paclitaxel conjugated with glycidylated pamam g4 dendrimers for cancer and parasite treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489794/
https://www.ncbi.nlm.nih.gov/pubmed/37687164
http://dx.doi.org/10.3390/molecules28176334
work_keys_str_mv AT uramłukasz exploringthepotentialoflapatinibfulvestrantandpaclitaxelconjugatedwithglycidylatedpamamg4dendrimersforcancerandparasitetreatment
AT wrobelkonrad exploringthepotentialoflapatinibfulvestrantandpaclitaxelconjugatedwithglycidylatedpamamg4dendrimersforcancerandparasitetreatment
AT walczakmałgorzata exploringthepotentialoflapatinibfulvestrantandpaclitaxelconjugatedwithglycidylatedpamamg4dendrimersforcancerandparasitetreatment
AT szymaszekzaneta exploringthepotentialoflapatinibfulvestrantandpaclitaxelconjugatedwithglycidylatedpamamg4dendrimersforcancerandparasitetreatment
AT twardowskamagdalena exploringthepotentialoflapatinibfulvestrantandpaclitaxelconjugatedwithglycidylatedpamamg4dendrimersforcancerandparasitetreatment
AT wołowiecstanisław exploringthepotentialoflapatinibfulvestrantandpaclitaxelconjugatedwithglycidylatedpamamg4dendrimersforcancerandparasitetreatment